Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
This map shows the geographic impact of B A Chabner's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B A Chabner with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B A Chabner more than expected).
This network shows the impact of papers produced by B A Chabner. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B A Chabner. The network helps show where B A Chabner may publish in the future.
Co-authorship network of co-authors of B A Chabner
This figure shows the co-authorship network connecting the top 25 collaborators of B A Chabner.
A scholar is included among the top collaborators of B A Chabner based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with B A Chabner. B A Chabner is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Pinedo, Herbert M., Dario Livio Longo, & B A Chabner. (1987). Cancer chemotherapy and biological response modifiers annual. Elsevier eBooks.221 indexed citations
6.
Allegra, Carmen J., et al.. (1987). Preliminary results of a phase II trial for the treatment of metastatic breast cancer with 5-fluorouracil and leucovorin.. PubMed. 199–202.12 indexed citations
7.
Allegra, C J, Robert L. Fine, J C Drake, & B A Chabner. (1986). ヒトMCF‐7乳がん細胞における細胞内葉酸プールに対するメトトレキセートの影響 プリン合成の直接阻害の証拠. Journal of Biological Chemistry. 261(14). 6478–6485.1 indexed citations
8.
Collins, Jerry M., Daniel S. Zaharko, Robert L. Dedrick, & B A Chabner. (1986). Potential roles for preclinical pharmacology in phase I clinical trials.. PubMed. 70(1). 73–80.155 indexed citations
9.
Chabner, B A & Herbert M. Pinedo. (1984). The cancer pharmacology annual. Elsevier eBooks.7 indexed citations
Jones, Richard A., et al.. (1979). Potential clinical applications of a new method for quantitation of plasma levels of 5-fluorouracil and 5-fluorodeoxyuridine.. PubMed. 66(1). 75–8.5 indexed citations
14.
Pinedo, H. M., et al.. (1977). Role of drug concentration, duration of exposure, and endogenous metabolites in determining methotrexate cytotoxicity.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 61(4). 709–15.64 indexed citations
15.
Jacobs, Samuel A., Ronald G. Stoller, B A Chabner, & D G Johns. (1977). Dose-dependent metabolism of methotrexate in man and rhesus monkeys.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 61(4). 651–6.45 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.